Carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP) represents one of the most alarming evolutionary developments in modern infectious diseases—a "superbug" that combines high-level antibiotic resistance with enhanced virulence. A new review published in Science Bulletin proposes a paradigm-shifting framework to address this growing global threat.
The review, Bin Cao, Jiankang Zhao and colleagues from the China-Japan Friendship Hospital, synthesizes current evidence on the convergence of resistance and hypervirulence in K. pneumoniae. The authors argue that the central clinical danger of convergence is not captured by the mere co-detection of resistance genes and virulence markers. Instead, the defining threat is the virulence phenotype that emerges from how resistance and virulence modules are expressed, regulated, and selected in specific host niches.
Two dominant convergence routes
The review identifies two primary pathways through which resistance-virulence convergence occurs: hypervirulent backgrounds acquiring resistance determinants, and carbapenem-resistant classical backgrounds acquiring virulence modules. These routes lead to distinct genomic architectures, including single-vehicle co-carriage (hybrid/fusion plasmids), two-plasmid synergy, and helper-plasmid facilitation models.
Virulence as a spectrum, not a binary state
A key insight of the framework is that convergent strains do not display uniform hypervirulence. Instead, they span a spectrum of outcomes: enhanced, adaptively attenuated, or maintained virulence intensities. This heterogeneity is shaped by context-dependent regulation, metabolic costs, and niche-specific selection pressures—explaining why genotype-positive strains often show discordant phenotypic outcomes.
High-risk clones under the spotlight
The review examines convergence trajectories in three high-risk clones: ST11 (dominant in Asia, particularly the ST11-KL64 sublineage), ST258 (globally prevalent with chromosomally encoded virulence), and ST23 (a canonical hypervirulent lineage acquiring resistance).
Clinical implications and future directions
The authors call for a phenotype-aware approach to diagnostics, urging integration of rapid molecular workflows with standardized functional assays to enable real-time risk stratification. Therapeutically, they advocate layered strategies combining molecular diagnostics, targeted anti-virulence agents, and carefully selected antimicrobial combinations guided by both resistance profiles and virulence phenotypes.
The review was supported by the National High Level Hospital Clinical Research Funding, the National Natural Science Foundation of China, and the CAMS Innovation Fund for Medical Sciences.
Science Bulletin